Current Studies


GeneFx Colon Field Experience Survey

GeneFx-Colon is a 634-transcript DNA microarray based signature developed for Stage II colon cancer using FFPE specimens. The assay identifies patients at higher risk of recurrence following surgery within 5 years. This test is not to be used independently for purposes of medical diagnosis, prognosis, or as the basis for making therapeutic decisions, but may be used in conjunction with other recognized tools.

We wish to conduct a research survey where we will be asking our physicians how the test results are being utilized vs traditional histo-factors to determine recurrence risk and treat/not treat.